#METABOLOMICS WORKBENCH kuppal2_20190625_115502 DATATRACK_ID:1842 STUDY_ID:ST001422 ANALYSIS_ID:AN002379 PROJECT_ID:PR000976 VERSION 1 CREATED_ON July 2, 2020, 2:40 pm #PROJECT PR:PROJECT_TITLE Aspirin Metabolomics in Colorectal Cancer Chemoprevention - Blood (Part I) PR:PROJECT_TYPE NIH/NCI R01CA188038 PR:PROJECT_SUMMARY Substantial evidence supports the effectiveness of aspirin for cancer PR:PROJECT_SUMMARY chemoprevention in addition to its well established role in cardiovascular PR:PROJECT_SUMMARY protection. In recent meta-analyses of randomized controlled trials in human, PR:PROJECT_SUMMARY daily aspirin use reduced incidence, metastasis and mortality from several PR:PROJECT_SUMMARY common types of cancer, especially colorectal cancer. The mechanism(s) by which PR:PROJECT_SUMMARY aspirin exerts an anticancer benefit is uncertain; numerous effects have been PR:PROJECT_SUMMARY described involving both cyclooxygenase-dependent and -independent pathways. The PR:PROJECT_SUMMARY goal of this research is to elucidate the key metabolic changes that are PR:PROJECT_SUMMARY responsible for the anticancer effects of aspirin in humans using untargeted PR:PROJECT_SUMMARY metabolomics analysis. Metabolomics, or global metabolite profiling, is an PR:PROJECT_SUMMARY emerging discipline that has the potential to transform the study of PR:PROJECT_SUMMARY pharmaceutical agents. Our innovative approach will use high-resolution mass PR:PROJECT_SUMMARY spectroscopy to detect thousands of metabolites in blood plasma and normal colon PR:PROJECT_SUMMARY mucosa biopsies that were collected from participants in the Aspirin/Folate PR:PROJECT_SUMMARY Polyp Prevention Study, a randomized, double-blind, placebo-controlled trial of PR:PROJECT_SUMMARY aspirin and/or folic acid supplementation for the prevention of colorectal PR:PROJECT_SUMMARY adenomas. Participants in the trial were assigned with equal probability to PR:PROJECT_SUMMARY three aspirin treatment arms (placebo, 81mg, or 325mg daily). Over the PR:PROJECT_SUMMARY three-year period, 81mg/day of aspirin reduced the risk of adenomas, whereas the PR:PROJECT_SUMMARY 325 mg/day dose had less effect. The aims of the current proposal are to PR:PROJECT_SUMMARY identify metabolomic signatures, including specific metabolites and metabolic PR:PROJECT_SUMMARY pathways, that are associated with aspirin treatment in blood and normal colon PR:PROJECT_SUMMARY mucosal tissue of participants after three years of randomized aspirin PR:PROJECT_SUMMARY treatment; and then to assess the associations of these metabolic signatures PR:PROJECT_SUMMARY with adenoma risk and whether they mediate the reductions in risk due to 81 PR:PROJECT_SUMMARY mg/day aspirin treatment. We will prioritize metabolites for study by evaluating PR:PROJECT_SUMMARY metabolite levels in patients from the placebo and treatment arms while PR:PROJECT_SUMMARY controlling the false discovery rate, use correlation analysis to enhance PR:PROJECT_SUMMARY identification of relevant metabolic modules associated with these prioritized PR:PROJECT_SUMMARY metabolites, and apply pathway mapping with post-hoc application of ion PR:PROJECT_SUMMARY dissociation spectroscopy to representative metabolites to confirm pathway PR:PROJECT_SUMMARY identification. Because aspirin is a multifunctional drug that is thought to PR:PROJECT_SUMMARY modify numerous pathways with potential roles in carcinogenesis, a global PR:PROJECT_SUMMARY discovery-based metabolomics approach is the best way to identify its key PR:PROJECT_SUMMARY activities. The public health significance of this work is substantial because PR:PROJECT_SUMMARY understanding the mechanism of aspirin's anticancer effects is key to optimizing PR:PROJECT_SUMMARY its use and to the development of novel drugs targeting the metabolic pathways PR:PROJECT_SUMMARY identified. PR:INSTITUTE Emory University Dept of Medicine PR:DEPARTMENT School of Medicine PR:LABORATORY Clinical Biomarkers Laboratory PR:LAST_NAME Tran PR:FIRST_NAME ViLinh PR:ADDRESS 615 Michael St, suite 225 PR:EMAIL vtran6@emory.edu PR:PHONE 4047275091 PR:FUNDING_SOURCE NIH/NCI R01CA188038 #STUDY ST:STUDY_TITLE Aspirin Metabolomics in Colorectal Cancer Chemoprevention - blood (part-II) ST:STUDY_SUMMARY Substantial evidence supports the effectiveness of aspirin for cancer ST:STUDY_SUMMARY chemoprevention in addition to its well established role in cardiovascular ST:STUDY_SUMMARY protection. In recent meta-analyses of randomized controlled trials in human, ST:STUDY_SUMMARY daily aspirin use reduced incidence, metastasis and mortality from several ST:STUDY_SUMMARY common types of cancer, especially colorectal cancer. The mechanism(s) by which ST:STUDY_SUMMARY aspirin exerts an anticancer benefit is uncertain; numerous effects have been ST:STUDY_SUMMARY described involving both cyclooxygenase-dependent and -independent pathways. The ST:STUDY_SUMMARY goal of this research is to elucidate the key metabolic changes that are ST:STUDY_SUMMARY responsible for the anticancer effects of aspirin in humans using untargeted ST:STUDY_SUMMARY metabolomics analysis. Metabolomics, or global metabolite profiling, is an ST:STUDY_SUMMARY emerging discipline that has the potential to transform the study of ST:STUDY_SUMMARY pharmaceutical agents. Our innovative approach will use high-resolution mass ST:STUDY_SUMMARY spectroscopy to detect thousands of metabolites in blood plasma that were ST:STUDY_SUMMARY collected from participants in the Aspirin/Folate Polyp Prevention Study, a ST:STUDY_SUMMARY randomized, double-blind, placebo-controlled trial of aspirin for the prevention ST:STUDY_SUMMARY of colorectal adenomas. Participants in the trial were assigned with equal ST:STUDY_SUMMARY probability to three aspirin treatment arms (placebo, 81mg, or 325mg daily). ST:STUDY_SUMMARY Over the three-year period, 81mg/day of aspirin reduced the risk of adenomas, ST:STUDY_SUMMARY whereas the 325 mg/day dose had less effect. The aims of the current proposal ST:STUDY_SUMMARY are to identify metabolomic signatures, including specific metabolites and ST:STUDY_SUMMARY metabolic pathways, that are associated with aspirin treatment in blood of ST:STUDY_SUMMARY participants after three years of randomized aspirin treatment; and then to ST:STUDY_SUMMARY assess the associations of these metabolic signatures with adenoma risk and ST:STUDY_SUMMARY whether they mediate the reductions in risk due to 81 mg/day aspirin treatment. ST:STUDY_SUMMARY We will prioritize metabolites for study by evaluating metabolite levels in ST:STUDY_SUMMARY patients from the placebo and treatment arms while controlling the false ST:STUDY_SUMMARY discovery rate, use correlation analysis to enhance identification of relevant ST:STUDY_SUMMARY metabolic modules associated with these prioritized metabolites, and apply ST:STUDY_SUMMARY pathway mapping with post-hoc application of ion dissociation spectroscopy to ST:STUDY_SUMMARY representative metabolites to confirm pathway identification. Because aspirin is ST:STUDY_SUMMARY a multifunctional drug that is thought to modify numerous pathways with ST:STUDY_SUMMARY potential roles in carcinogenesis, a global discovery-based metabolomics ST:STUDY_SUMMARY approach is the best way to identify its key activities. The public health ST:STUDY_SUMMARY significance of this work is substantial because understanding the mechanism of ST:STUDY_SUMMARY aspirin's anticancer effects is key to optimizing its use and to the development ST:STUDY_SUMMARY of novel drugs targeting the metabolic pathways identified. ST:INSTITUTE Emory University ST:DEPARTMENT School of Medicine ST:LABORATORY Clincal Biomarkers Laboratory ST:LAST_NAME Uppal ST:FIRST_NAME Karan ST:ADDRESS 615 Michael St, Suite 225 ST:EMAIL kuppal2@emory.edu ST:PHONE (404) 727 5027 ST:TOTAL_SUBJECTS 600 ST:STUDY_COMMENTS Aspirin Metabolomics Priority 1 #SUBJECT SU:SUBJECT_TYPE Human SU:SUBJECT_SPECIES Homo sapiens SU:TAXONOMY_ID 9606 SU:AGE_OR_AGE_RANGE 29-82 SU:GENDER Male and female #SUBJECT_SAMPLE_FACTORS: SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data SUBJECT_SAMPLE_FACTORS Quality Control nist_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160120_001 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_1a_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160120_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000332_1 Sex:1 | Treatment:2 SubjectID=21115; RAW_FILE_NAME=VT_160120_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000306_1 Sex:1 | Treatment:- SubjectID=20966; RAW_FILE_NAME=VT_160120_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000278_1 Sex:1 | Treatment:1 SubjectID=20753; RAW_FILE_NAME=VT_160120_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006690_1 Sex:1 | Treatment:- SubjectID=71030; RAW_FILE_NAME=VT_160120_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000341_1 Sex:2 | Treatment:- SubjectID=40553; RAW_FILE_NAME=VT_160120_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000293_1 Sex:1 | Treatment:- SubjectID=20843; RAW_FILE_NAME=VT_160120_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000279_1 Sex:1 | Treatment:1 SubjectID=20753; RAW_FILE_NAME=VT_160120_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000333_1 Sex:1 | Treatment:- SubjectID=21160; RAW_FILE_NAME=VT_160120_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000335_1 Sex:1 | Treatment:2 SubjectID=21181; RAW_FILE_NAME=VT_160120_061 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001464_1 Sex:2 | Treatment:2 SubjectID=40586; RAW_FILE_NAME=VT_160120_067 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_1b_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160120_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000292_1 Sex:1 | Treatment:- SubjectID=20843; RAW_FILE_NAME=VT_160120_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000347_1 Sex:2 | Treatment:2 SubjectID=40586; RAW_FILE_NAME=VT_160120_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000343_1 Sex:2 | Treatment:- SubjectID=40553; RAW_FILE_NAME=VT_160120_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000213_1 Sex:1 | Treatment:- SubjectID=71030; RAW_FILE_NAME=VT_160120_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000331_1 Sex:1 | Treatment:2 SubjectID=21115; RAW_FILE_NAME=VT_160120_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000334_1 Sex:1 | Treatment:- SubjectID=21160; RAW_FILE_NAME=VT_160120_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000307_1 Sex:1 | Treatment:- SubjectID=20966; RAW_FILE_NAME=VT_160120_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005976_1 Sex:1 | Treatment:1 SubjectID=40621; RAW_FILE_NAME=VT_160120_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000349_1 Sex:1 | Treatment:1 SubjectID=40621; RAW_FILE_NAME=VT_160120_127 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000944_1 Sex:1 | Treatment:2 SubjectID=21181; RAW_FILE_NAME=VT_160120_133 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_1c_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160120_139 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_2a_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160121_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000417_1 Sex:2 | Treatment:- SubjectID=20068; RAW_FILE_NAME=VT_160121_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000406_1 Sex:1 | Treatment:2 SubjectID=41060; RAW_FILE_NAME=VT_160121_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000394_1 Sex:1 | Treatment:- SubjectID=40979; RAW_FILE_NAME=VT_160121_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40016031_1 Sex:1 | Treatment:2 SubjectID=41060; RAW_FILE_NAME=VT_160121_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000381_1 Sex:2 | Treatment:1 SubjectID=40867; RAW_FILE_NAME=VT_160121_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000434_1 Sex:1 | Treatment:2 SubjectID=20215; RAW_FILE_NAME=VT_160121_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000439_1 Sex:2 | Treatment:1 SubjectID=20259; RAW_FILE_NAME=VT_160121_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000877_1 Sex:2 | Treatment:- SubjectID=20068; RAW_FILE_NAME=VT_160121_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000395_1 Sex:1 | Treatment:- SubjectID=40979; RAW_FILE_NAME=VT_160121_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000433_1 Sex:1 | Treatment:2 SubjectID=20215; RAW_FILE_NAME=VT_160121_061 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_2b_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160121_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000440_1 Sex:2 | Treatment:1 SubjectID=20259; RAW_FILE_NAME=VT_160121_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000408_1 Sex:1 | Treatment:2 SubjectID=41071; RAW_FILE_NAME=VT_160121_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000380_1 Sex:2 | Treatment:1 SubjectID=40867; RAW_FILE_NAME=VT_160121_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40016032_1 Sex:1 | Treatment:2 SubjectID=41071; RAW_FILE_NAME=VT_160121_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000468_1 Sex:2 | Treatment:- SubjectID=20518; RAW_FILE_NAME=VT_160121_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005553_1 Sex:2 | Treatment:- SubjectID=20518; RAW_FILE_NAME=VT_160121_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006806_1 Sex:1 | Treatment:2 SubjectID=40799; RAW_FILE_NAME=VT_160121_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000370_1 Sex:1 | Treatment:- SubjectID=40788; RAW_FILE_NAME=VT_160121_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000369_1 Sex:1 | Treatment:- SubjectID=40788; RAW_FILE_NAME=VT_160121_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000371_1 Sex:1 | Treatment:2 SubjectID=40799; RAW_FILE_NAME=VT_160121_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_2c_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160121_133 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_3a_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160122_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105580_1 Sex:1 | Treatment:2 SubjectID=30394; RAW_FILE_NAME=VT_160122_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105659_1 Sex:1 | Treatment:2 SubjectID=60702; RAW_FILE_NAME=VT_160122_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105537_1 Sex:2 | Treatment:- SubjectID=22070; RAW_FILE_NAME=VT_160122_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105600_1 Sex:2 | Treatment:- SubjectID=30541; RAW_FILE_NAME=VT_160122_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006455_1 Sex:1 | Treatment:2 SubjectID=60702; RAW_FILE_NAME=VT_160122_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000471_1 Sex:2 | Treatment:- SubjectID=20530; RAW_FILE_NAME=VT_160122_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105548_1 Sex:2 | Treatment:1 SubjectID=30115; RAW_FILE_NAME=VT_160122_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105504_1 Sex:2 | Treatment:- SubjectID=21822; RAW_FILE_NAME=VT_160122_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105689_1 Sex:1 | Treatment:1 SubjectID=60959; RAW_FILE_NAME=VT_160122_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005835_1 Sex:2 | Treatment:- SubjectID=30541; RAW_FILE_NAME=VT_160122_061 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_3b_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160122_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005737_1 Sex:2 | Treatment:1 SubjectID=30115; RAW_FILE_NAME=VT_160122_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105581_1 Sex:1 | Treatment:2 SubjectID=30394; RAW_FILE_NAME=VT_160122_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000472_1 Sex:2 | Treatment:- SubjectID=20530; RAW_FILE_NAME=VT_160122_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005828_1 Sex:1 | Treatment:2 SubjectID=22048; RAW_FILE_NAME=VT_160122_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000482_1 Sex:1 | Treatment:1 SubjectID=20595; RAW_FILE_NAME=VT_160122_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105534_1 Sex:1 | Treatment:2 SubjectID=22048; RAW_FILE_NAME=VT_160122_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005702_1 Sex:2 | Treatment:- SubjectID=21822; RAW_FILE_NAME=VT_160122_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015140_1 Sex:1 | Treatment:1 SubjectID=20595; RAW_FILE_NAME=VT_160122_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105536_1 Sex:2 | Treatment:- SubjectID=22070; RAW_FILE_NAME=VT_160122_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105690_1 Sex:1 | Treatment:1 SubjectID=60959; RAW_FILE_NAME=VT_160122_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_3c_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160122_133 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_4a_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160123_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105883_1 Sex:1 | Treatment:- SubjectID=21394; RAW_FILE_NAME=VT_160123_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006950_1 Sex:2 | Treatment:2 SubjectID=80590; RAW_FILE_NAME=VT_160123_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105963_1 Sex:2 | Treatment:2 SubjectID=80590; RAW_FILE_NAME=VT_160123_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106004_1 Sex:1 | Treatment:2 SubjectID=80994; RAW_FILE_NAME=VT_160123_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105974_1 Sex:1 | Treatment:- SubjectID=80691; RAW_FILE_NAME=VT_160123_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105923_1 Sex:1 | Treatment:2 SubjectID=21697; RAW_FILE_NAME=VT_160123_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106005_1 Sex:1 | Treatment:2 SubjectID=80994; RAW_FILE_NAME=VT_160123_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106051_1 Sex:1 | Treatment:- SubjectID=10258; RAW_FILE_NAME=VT_160123_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001704_1 Sex:1 | Treatment:- SubjectID=60465; RAW_FILE_NAME=VT_160123_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105999_1 Sex:1 | Treatment:1 SubjectID=80939; RAW_FILE_NAME=VT_160123_061 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_4b_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160123_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000771_1 Sex:1 | Treatment:- SubjectID=10258; RAW_FILE_NAME=VT_160123_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106045_1 Sex:1 | Treatment:1 SubjectID=10203; RAW_FILE_NAME=VT_160123_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015928_1 Sex:1 | Treatment:1 SubjectID=10203; RAW_FILE_NAME=VT_160123_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106002_1 Sex:1 | Treatment:2 SubjectID=80972; RAW_FILE_NAME=VT_160123_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006629_1 Sex:1 | Treatment:2 SubjectID=80972; RAW_FILE_NAME=VT_160123_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105998_1 Sex:1 | Treatment:1 SubjectID=80939; RAW_FILE_NAME=VT_160123_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105776_1 Sex:1 | Treatment:- SubjectID=60465; RAW_FILE_NAME=VT_160123_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105973_1 Sex:1 | Treatment:- SubjectID=80691; RAW_FILE_NAME=VT_160123_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105924_1 Sex:1 | Treatment:2 SubjectID=21697; RAW_FILE_NAME=VT_160123_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105884_1 Sex:1 | Treatment:- SubjectID=21394; RAW_FILE_NAME=VT_160123_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_4c_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160123_133 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_5a_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160125_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106476_1 Sex:1 | Treatment:- SubjectID=41824; RAW_FILE_NAME=VT_160125_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106136_1 Sex:2 | Treatment:2 SubjectID=90660; RAW_FILE_NAME=VT_160125_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106066_1 Sex:2 | Treatment:1 SubjectID=10392; RAW_FILE_NAME=VT_160125_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106529_1 Sex:1 | Treatment:2 SubjectID=50410; RAW_FILE_NAME=VT_160125_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106019_1 Sex:1 | Treatment:- SubjectID=10326; RAW_FILE_NAME=VT_160125_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106173_1 Sex:2 | Treatment:2 SubjectID=91212; RAW_FILE_NAME=VT_160125_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106057_1 Sex:1 | Treatment:- SubjectID=10326; RAW_FILE_NAME=VT_160125_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106065_1 Sex:2 | Treatment:1 SubjectID=10392; RAW_FILE_NAME=VT_160125_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106133_1 Sex:2 | Treatment:- SubjectID=90659; RAW_FILE_NAME=VT_160125_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106172_1 Sex:2 | Treatment:2 SubjectID=91212; RAW_FILE_NAME=VT_160125_061 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_5b_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160125_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106475_1 Sex:1 | Treatment:- SubjectID=41824; RAW_FILE_NAME=VT_160125_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106135_1 Sex:2 | Treatment:2 SubjectID=90660; RAW_FILE_NAME=VT_160125_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106495_1 Sex:1 | Treatment:2 SubjectID=50128; RAW_FILE_NAME=VT_160125_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106635_1 Sex:1 | Treatment:1 SubjectID=51353; RAW_FILE_NAME=VT_160125_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006227_1 Sex:1 | Treatment:2 SubjectID=50128; RAW_FILE_NAME=VT_160125_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015882_1 Sex:2 | Treatment:- SubjectID=90659; RAW_FILE_NAME=VT_160125_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106530_1 Sex:1 | Treatment:2 SubjectID=50410; RAW_FILE_NAME=VT_160125_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106634_1 Sex:1 | Treatment:1 SubjectID=51353; RAW_FILE_NAME=VT_160125_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106587_1 Sex:2 | Treatment:2 SubjectID=61108; RAW_FILE_NAME=VT_160125_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006268_1 Sex:2 | Treatment:2 SubjectID=61108; RAW_FILE_NAME=VT_160125_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_5c_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160125_133 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_6a_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160126_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006083_1 Sex:1 | Treatment:1 SubjectID=41374; RAW_FILE_NAME=VT_160126_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106227_1 Sex:1 | Treatment:- SubjectID=41510; RAW_FILE_NAME=VT_160126_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005940_1 Sex:2 | Treatment:2 SubjectID=41140; RAW_FILE_NAME=VT_160126_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106231_1 Sex:2 | Treatment:- SubjectID=41543; RAW_FILE_NAME=VT_160126_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106226_1 Sex:1 | Treatment:- SubjectID=41510; RAW_FILE_NAME=VT_160126_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001533_1 Sex:1 | Treatment:- SubjectID=41600; RAW_FILE_NAME=VT_160126_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106178_1 Sex:2 | Treatment:1 SubjectID=91245; RAW_FILE_NAME=VT_160126_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001152_1 Sex:2 | Treatment:1 SubjectID=91245; RAW_FILE_NAME=VT_160126_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015174_1 Sex:1 | Treatment:1 SubjectID=11530; RAW_FILE_NAME=VT_160126_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106251_1 Sex:2 | Treatment:1 SubjectID=41677; RAW_FILE_NAME=VT_160126_061 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_6b_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160126_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006464_1 Sex:2 | Treatment:- SubjectID=70095; RAW_FILE_NAME=VT_160126_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106301_1 Sex:1 | Treatment:1 SubjectID=11530; RAW_FILE_NAME=VT_160126_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005972_1 Sex:1 | Treatment:2 SubjectID=41611; RAW_FILE_NAME=VT_160126_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106336_1 Sex:2 | Treatment:- SubjectID=70095; RAW_FILE_NAME=VT_160126_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006811_1 Sex:2 | Treatment:- SubjectID=41543; RAW_FILE_NAME=VT_160126_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106241_1 Sex:1 | Treatment:- SubjectID=41600; RAW_FILE_NAME=VT_160126_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106182_1 Sex:2 | Treatment:2 SubjectID=41140; RAW_FILE_NAME=VT_160126_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106243_1 Sex:1 | Treatment:2 SubjectID=41611; RAW_FILE_NAME=VT_160126_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106211_1 Sex:1 | Treatment:1 SubjectID=41374; RAW_FILE_NAME=VT_160126_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106252_1 Sex:2 | Treatment:1 SubjectID=41677; RAW_FILE_NAME=VT_160126_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_6c_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160126_133 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_7a_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160127_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106415_1 Sex:2 | Treatment:- SubjectID=30866; RAW_FILE_NAME=VT_160127_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106409_1 Sex:1 | Treatment:1 SubjectID=30833; RAW_FILE_NAME=VT_160127_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106418_1 Sex:1 | Treatment:2 SubjectID=30888; RAW_FILE_NAME=VT_160127_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106416_1 Sex:1 | Treatment:- SubjectID=30877; RAW_FILE_NAME=VT_160127_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106402_1 Sex:1 | Treatment:2 SubjectID=30800; RAW_FILE_NAME=VT_160127_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106350_1 Sex:2 | Treatment:2 SubjectID=70264; RAW_FILE_NAME=VT_160127_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106417_1 Sex:1 | Treatment:- SubjectID=30877; RAW_FILE_NAME=VT_160127_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106414_1 Sex:2 | Treatment:- SubjectID=30866; RAW_FILE_NAME=VT_160127_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106419_1 Sex:1 | Treatment:2 SubjectID=30888; RAW_FILE_NAME=VT_160127_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106383_1 Sex:1 | Treatment:2 SubjectID=70556; RAW_FILE_NAME=VT_160127_061 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_7b_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160127_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106352_1 Sex:1 | Treatment:2 SubjectID=70275; RAW_FILE_NAME=VT_160127_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106382_1 Sex:1 | Treatment:2 SubjectID=70556; RAW_FILE_NAME=VT_160127_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106376_1 Sex:2 | Treatment:- SubjectID=70501; RAW_FILE_NAME=VT_160127_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006697_1 Sex:2 | Treatment:2 SubjectID=70264; RAW_FILE_NAME=VT_160127_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106353_1 Sex:1 | Treatment:2 SubjectID=70275; RAW_FILE_NAME=VT_160127_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106425_1 Sex:1 | Treatment:2 SubjectID=30912; RAW_FILE_NAME=VT_160127_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005863_1 Sex:1 | Treatment:2 SubjectID=30800; RAW_FILE_NAME=VT_160127_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005826_1 Sex:1 | Treatment:1 SubjectID=30833; RAW_FILE_NAME=VT_160127_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006551_1 Sex:2 | Treatment:- SubjectID=70501; RAW_FILE_NAME=VT_160127_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106424_1 Sex:1 | Treatment:2 SubjectID=30912; RAW_FILE_NAME=VT_160127_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_7c_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160127_133 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_8a_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160128_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106460_1 Sex:1 | Treatment:1 SubjectID=31182; RAW_FILE_NAME=VT_160128_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006968_1 Sex:2 | Treatment:1 SubjectID=90121; RAW_FILE_NAME=VT_160128_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000604_1 Sex:2 | Treatment:1 SubjectID=40171; RAW_FILE_NAME=VT_160128_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106454_1 Sex:1 | Treatment:- SubjectID=31127; RAW_FILE_NAME=VT_160128_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106452_1 Sex:1 | Treatment:- SubjectID=31116; RAW_FILE_NAME=VT_160128_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106456_1 Sex:2 | Treatment:- SubjectID=31138; RAW_FILE_NAME=VT_160128_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001420_1 Sex:1 | Treatment:2 SubjectID=40138; RAW_FILE_NAME=VT_160128_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015709_1 Sex:2 | Treatment:- SubjectID=31138; RAW_FILE_NAME=VT_160128_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000554_1 Sex:2 | Treatment:1 SubjectID=90121; RAW_FILE_NAME=VT_160128_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106453_1 Sex:1 | Treatment:- SubjectID=31116; RAW_FILE_NAME=VT_160128_061 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_8b_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160128_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000514_1 Sex:1 | Treatment:1 SubjectID=81031; RAW_FILE_NAME=VT_160128_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015708_1 Sex:1 | Treatment:- SubjectID=31127; RAW_FILE_NAME=VT_160128_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015811_1 Sex:1 | Treatment:1 SubjectID=81031; RAW_FILE_NAME=VT_160128_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106435_1 Sex:2 | Treatment:2 SubjectID=30967; RAW_FILE_NAME=VT_160128_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000603_1 Sex:2 | Treatment:1 SubjectID=40171; RAW_FILE_NAME=VT_160128_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000598_1 Sex:1 | Treatment:2 SubjectID=40138; RAW_FILE_NAME=VT_160128_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106434_1 Sex:2 | Treatment:2 SubjectID=30967; RAW_FILE_NAME=VT_160128_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106461_1 Sex:1 | Treatment:1 SubjectID=31182; RAW_FILE_NAME=VT_160128_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106428_1 Sex:1 | Treatment:- SubjectID=30934; RAW_FILE_NAME=VT_160128_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106429_1 Sex:1 | Treatment:- SubjectID=30934; RAW_FILE_NAME=VT_160128_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_8c_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160128_133 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_9a_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160129_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001677_1 Sex:1 | Treatment:1 SubjectID=10853; RAW_FILE_NAME=VT_160129_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001459_1 Sex:1 | Treatment:1 SubjectID=40509; RAW_FILE_NAME=VT_160129_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000682_1 Sex:1 | Treatment:- SubjectID=50598; RAW_FILE_NAME=VT_160129_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001816_1 Sex:2 | Treatment:2 SubjectID=81075; RAW_FILE_NAME=VT_160129_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001180_1 Sex:2 | Treatment:2 SubjectID=81075; RAW_FILE_NAME=VT_160129_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001752_1 Sex:1 | Treatment:1 SubjectID=80737; RAW_FILE_NAME=VT_160129_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001163_1 Sex:2 | Treatment:1 SubjectID=80816; RAW_FILE_NAME=VT_160129_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000612_1 Sex:1 | Treatment:1 SubjectID=40217; RAW_FILE_NAME=VT_160129_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000819_1 Sex:1 | Treatment:1 SubjectID=10853; RAW_FILE_NAME=VT_160129_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015805_1 Sex:1 | Treatment:1 SubjectID=80737; RAW_FILE_NAME=VT_160129_061 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_9b_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160129_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001800_1 Sex:1 | Treatment:1 SubjectID=90244; RAW_FILE_NAME=VT_160129_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000683_1 Sex:1 | Treatment:- SubjectID=50598; RAW_FILE_NAME=VT_160129_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001778_1 Sex:2 | Treatment:1 SubjectID=90010; RAW_FILE_NAME=VT_160129_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000611_1 Sex:1 | Treatment:1 SubjectID=40217; RAW_FILE_NAME=VT_160129_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006664_1 Sex:2 | Treatment:1 SubjectID=90010; RAW_FILE_NAME=VT_160129_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001762_1 Sex:2 | Treatment:1 SubjectID=80816; RAW_FILE_NAME=VT_160129_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001205_1 Sex:1 | Treatment:- SubjectID=80636; RAW_FILE_NAME=VT_160129_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000574_1 Sex:1 | Treatment:1 SubjectID=90244; RAW_FILE_NAME=VT_160129_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000654_1 Sex:1 | Treatment:1 SubjectID=40509; RAW_FILE_NAME=VT_160129_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001747_1 Sex:1 | Treatment:- SubjectID=80636; RAW_FILE_NAME=VT_160129_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_9c_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160129_133 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_10a_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160130_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001862_1 Sex:2 | Treatment:1 SubjectID=80568; RAW_FILE_NAME=VT_160130_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001239_1 Sex:2 | Treatment:- SubjectID=80344; RAW_FILE_NAME=VT_160130_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001901_1 Sex:1 | Treatment:- SubjectID=90446; RAW_FILE_NAME=VT_160130_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001853_1 Sex:2 | Treatment:- SubjectID=80490; RAW_FILE_NAME=VT_160130_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105958_1 Sex:2 | Treatment:1 SubjectID=80568; RAW_FILE_NAME=VT_160130_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006946_1 Sex:1 | Treatment:- SubjectID=90446; RAW_FILE_NAME=VT_160130_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106568_1 Sex:2 | Treatment:1 SubjectID=91470; RAW_FILE_NAME=VT_160130_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001871_1 Sex:1 | Treatment:- SubjectID=91458; RAW_FILE_NAME=VT_160130_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001884_1 Sex:1 | Treatment:1 SubjectID=91560; RAW_FILE_NAME=VT_160130_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001192_1 Sex:2 | Treatment:- SubjectID=80490; RAW_FILE_NAME=VT_160130_061 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_10b_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160130_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105962_1 Sex:1 | Treatment:- SubjectID=80580; RAW_FILE_NAME=VT_160130_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001835_1 Sex:2 | Treatment:- SubjectID=80344; RAW_FILE_NAME=VT_160130_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001187_1 Sex:2 | Treatment:- SubjectID=80412; RAW_FILE_NAME=VT_160130_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015200_1 Sex:1 | Treatment:- SubjectID=91458; RAW_FILE_NAME=VT_160130_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001844_1 Sex:2 | Treatment:- SubjectID=80412; RAW_FILE_NAME=VT_160130_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001876_1 Sex:2 | Treatment:1 SubjectID=91470; RAW_FILE_NAME=VT_160130_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015193_1 Sex:1 | Treatment:1 SubjectID=91560; RAW_FILE_NAME=VT_160130_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001849_1 Sex:1 | Treatment:1 SubjectID=80467; RAW_FILE_NAME=VT_160130_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001190_1 Sex:1 | Treatment:1 SubjectID=80467; RAW_FILE_NAME=VT_160130_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001867_1 Sex:1 | Treatment:- SubjectID=80580; RAW_FILE_NAME=VT_160130_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_10c_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160130_133 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_11a_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160201_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106156_1 Sex:2 | Treatment:2 SubjectID=90793; RAW_FILE_NAME=VT_160201_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106816_1 Sex:1 | Treatment:2 SubjectID=91032; RAW_FILE_NAME=VT_160201_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001966_1 Sex:1 | Treatment:1 SubjectID=90962; RAW_FILE_NAME=VT_160201_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006945_1 Sex:1 | Treatment:- SubjectID=90490; RAW_FILE_NAME=VT_160201_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40007084_1 Sex:1 | Treatment:2 SubjectID=91346; RAW_FILE_NAME=VT_160201_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40007018_1 Sex:2 | Treatment:1 SubjectID=91043; RAW_FILE_NAME=VT_160201_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001937_1 Sex:2 | Treatment:1 SubjectID=90738; RAW_FILE_NAME=VT_160201_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002007_1 Sex:1 | Treatment:2 SubjectID=91346; RAW_FILE_NAME=VT_160201_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001910_1 Sex:1 | Treatment:- SubjectID=90490; RAW_FILE_NAME=VT_160201_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006979_1 Sex:2 | Treatment:1 SubjectID=90951; RAW_FILE_NAME=VT_160201_061 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_11b_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160201_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106181_1 Sex:2 | Treatment:2 SubjectID=91234; RAW_FILE_NAME=VT_160201_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001944_1 Sex:2 | Treatment:2 SubjectID=90793; RAW_FILE_NAME=VT_160201_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001976_1 Sex:1 | Treatment:2 SubjectID=91032; RAW_FILE_NAME=VT_160201_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001975_1 Sex:2 | Treatment:1 SubjectID=91043; RAW_FILE_NAME=VT_160201_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001964_1 Sex:2 | Treatment:1 SubjectID=90951; RAW_FILE_NAME=VT_160201_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001996_1 Sex:2 | Treatment:2 SubjectID=91234; RAW_FILE_NAME=VT_160201_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001962_1 Sex:1 | Treatment:2 SubjectID=90940; RAW_FILE_NAME=VT_160201_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106146_1 Sex:2 | Treatment:1 SubjectID=90738; RAW_FILE_NAME=VT_160201_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006978_1 Sex:1 | Treatment:2 SubjectID=90940; RAW_FILE_NAME=VT_160201_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40007016_1 Sex:1 | Treatment:1 SubjectID=90962; RAW_FILE_NAME=VT_160201_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_11c_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160201_133 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_12a_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160202_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000243_1 Sex:1 | Treatment:2 SubjectID=80063; RAW_FILE_NAME=VT_160202_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002108_1 Sex:1 | Treatment:2 SubjectID=80063; RAW_FILE_NAME=VT_160202_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006635_1 Sex:1 | Treatment:2 SubjectID=61119; RAW_FILE_NAME=VT_160202_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105686_1 Sex:2 | Treatment:1 SubjectID=60915; RAW_FILE_NAME=VT_160202_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40007082_1 Sex:1 | Treatment:1 SubjectID=91414; RAW_FILE_NAME=VT_160202_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002033_1 Sex:2 | Treatment:1 SubjectID=60915; RAW_FILE_NAME=VT_160202_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002041_1 Sex:1 | Treatment:- SubjectID=60981; RAW_FILE_NAME=VT_160202_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002040_1 Sex:1 | Treatment:1 SubjectID=60970; RAW_FILE_NAME=VT_160202_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002134_1 Sex:1 | Treatment:2 SubjectID=61119; RAW_FILE_NAME=VT_160202_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40007105_1 Sex:1 | Treatment:- SubjectID=91390; RAW_FILE_NAME=VT_160202_061 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_12b_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160202_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006506_1 Sex:1 | Treatment:- SubjectID=61018; RAW_FILE_NAME=VT_160202_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002012_1 Sex:1 | Treatment:- SubjectID=91390; RAW_FILE_NAME=VT_160202_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006634_1 Sex:1 | Treatment:1 SubjectID=60970; RAW_FILE_NAME=VT_160202_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002044_1 Sex:1 | Treatment:- SubjectID=61018; RAW_FILE_NAME=VT_160202_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001687_1 Sex:1 | Treatment:- SubjectID=80142; RAW_FILE_NAME=VT_160202_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002047_1 Sex:2 | Treatment:2 SubjectID=61040; RAW_FILE_NAME=VT_160202_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002016_1 Sex:1 | Treatment:1 SubjectID=91414; RAW_FILE_NAME=VT_160202_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015354_1 Sex:2 | Treatment:2 SubjectID=61040; RAW_FILE_NAME=VT_160202_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105696_1 Sex:1 | Treatment:- SubjectID=60981; RAW_FILE_NAME=VT_160202_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002121_1 Sex:1 | Treatment:- SubjectID=80142; RAW_FILE_NAME=VT_160202_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_12c_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160202_133 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_13a_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160203_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002177_1 Sex:2 | Treatment:- SubjectID=61499; RAW_FILE_NAME=VT_160203_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001366_1 Sex:2 | Treatment:1 SubjectID=70387; RAW_FILE_NAME=VT_160203_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015952_1 Sex:2 | Treatment:1 SubjectID=61545; RAW_FILE_NAME=VT_160203_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106680_1 Sex:2 | Treatment:- SubjectID=61499; RAW_FILE_NAME=VT_160203_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006375_1 Sex:2 | Treatment:2 SubjectID=61556; RAW_FILE_NAME=VT_160203_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002188_1 Sex:1 | Treatment:1 SubjectID=61578; RAW_FILE_NAME=VT_160203_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40020696_1 Sex:2 | Treatment:- SubjectID=61411; RAW_FILE_NAME=VT_160203_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002151_1 Sex:1 | Treatment:2 SubjectID=61242; RAW_FILE_NAME=VT_160203_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002240_1 Sex:2 | Treatment:1 SubjectID=70657; RAW_FILE_NAME=VT_160203_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002215_1 Sex:1 | Treatment:1 SubjectID=70398; RAW_FILE_NAME=VT_160203_061 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_13b_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160203_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002213_1 Sex:2 | Treatment:1 SubjectID=70387; RAW_FILE_NAME=VT_160203_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002184_1 Sex:2 | Treatment:2 SubjectID=61556; RAW_FILE_NAME=VT_160203_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002169_1 Sex:2 | Treatment:- SubjectID=61411; RAW_FILE_NAME=VT_160203_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002182_1 Sex:2 | Treatment:1 SubjectID=61545; RAW_FILE_NAME=VT_160203_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006386_1 Sex:1 | Treatment:1 SubjectID=61578; RAW_FILE_NAME=VT_160203_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006639_1 Sex:1 | Treatment:2 SubjectID=61635; RAW_FILE_NAME=VT_160203_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106648_1 Sex:1 | Treatment:2 SubjectID=61242; RAW_FILE_NAME=VT_160203_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002199_1 Sex:1 | Treatment:2 SubjectID=61635; RAW_FILE_NAME=VT_160203_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106395_1 Sex:2 | Treatment:1 SubjectID=70657; RAW_FILE_NAME=VT_160203_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006700_1 Sex:1 | Treatment:1 SubjectID=70398; RAW_FILE_NAME=VT_160203_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_13c_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160203_133 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_14a_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160204_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002307_1 Sex:2 | Treatment:2 SubjectID=70152; RAW_FILE_NAME=VT_160204_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001335_1 Sex:2 | Treatment:2 SubjectID=70141; RAW_FILE_NAME=VT_160204_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002355_1 Sex:1 | Treatment:- SubjectID=40687; RAW_FILE_NAME=VT_160204_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001338_1 Sex:2 | Treatment:2 SubjectID=70152; RAW_FILE_NAME=VT_160204_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000652_1 Sex:1 | Treatment:2 SubjectID=40496; RAW_FILE_NAME=VT_160204_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001353_1 Sex:1 | Treatment:2 SubjectID=70242; RAW_FILE_NAME=VT_160204_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002253_1 Sex:2 | Treatment:2 SubjectID=70758; RAW_FILE_NAME=VT_160204_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001398_1 Sex:2 | Treatment:1 SubjectID=70815; RAW_FILE_NAME=VT_160204_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002340_1 Sex:1 | Treatment:2 SubjectID=40496; RAW_FILE_NAME=VT_160204_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006809_1 Sex:2 | Treatment:- SubjectID=41500; RAW_FILE_NAME=VT_160204_061 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_14b_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160204_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106234_1 Sex:1 | Treatment:1 SubjectID=41554; RAW_FILE_NAME=VT_160204_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002287_1 Sex:1 | Treatment:2 SubjectID=70040; RAW_FILE_NAME=VT_160204_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002379_1 Sex:1 | Treatment:1 SubjectID=41554; RAW_FILE_NAME=VT_160204_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002305_1 Sex:2 | Treatment:2 SubjectID=70141; RAW_FILE_NAME=VT_160204_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001321_1 Sex:1 | Treatment:2 SubjectID=70040; RAW_FILE_NAME=VT_160204_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002377_1 Sex:2 | Treatment:- SubjectID=41500; RAW_FILE_NAME=VT_160204_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001470_1 Sex:1 | Treatment:- SubjectID=40687; RAW_FILE_NAME=VT_160204_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000005_1 Sex:2 | Treatment:2 SubjectID=70758; RAW_FILE_NAME=VT_160204_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002258_1 Sex:2 | Treatment:1 SubjectID=70815; RAW_FILE_NAME=VT_160204_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002319_1 Sex:1 | Treatment:2 SubjectID=70242; RAW_FILE_NAME=VT_160204_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_14c_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160204_133 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_15a_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160205_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002456_1 Sex:1 | Treatment:1 SubjectID=50442; RAW_FILE_NAME=VT_160205_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006193_1 Sex:1 | Treatment:- SubjectID=50486; RAW_FILE_NAME=VT_160205_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002465_1 Sex:2 | Treatment:2 SubjectID=50554; RAW_FILE_NAME=VT_160205_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106210_1 Sex:2 | Treatment:- SubjectID=41363; RAW_FILE_NAME=VT_160205_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006197_1 Sex:1 | Treatment:1 SubjectID=50230; RAW_FILE_NAME=VT_160205_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002405_1 Sex:2 | Treatment:- SubjectID=41229; RAW_FILE_NAME=VT_160205_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015321_1 Sex:2 | Treatment:2 SubjectID=50554; RAW_FILE_NAME=VT_160205_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002480_1 Sex:1 | Treatment:2 SubjectID=50880; RAW_FILE_NAME=VT_160205_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002482_1 Sex:2 | Treatment:1 SubjectID=50890; RAW_FILE_NAME=VT_160205_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000733_1 Sex:1 | Treatment:2 SubjectID=50880; RAW_FILE_NAME=VT_160205_061 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_15b_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160205_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106193_1 Sex:2 | Treatment:- SubjectID=41229; RAW_FILE_NAME=VT_160205_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002462_1 Sex:1 | Treatment:2 SubjectID=50497; RAW_FILE_NAME=VT_160205_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002433_1 Sex:1 | Treatment:1 SubjectID=50230; RAW_FILE_NAME=VT_160205_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000665_1 Sex:1 | Treatment:1 SubjectID=50442; RAW_FILE_NAME=VT_160205_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006085_1 Sex:1 | Treatment:2 SubjectID=50497; RAW_FILE_NAME=VT_160205_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002460_1 Sex:1 | Treatment:- SubjectID=50486; RAW_FILE_NAME=VT_160205_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000735_1 Sex:2 | Treatment:1 SubjectID=50890; RAW_FILE_NAME=VT_160205_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002416_1 Sex:2 | Treatment:- SubjectID=41363; RAW_FILE_NAME=VT_160205_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015327_1 Sex:1 | Treatment:1 SubjectID=50475; RAW_FILE_NAME=VT_160205_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002459_1 Sex:1 | Treatment:1 SubjectID=50475; RAW_FILE_NAME=VT_160205_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_15c_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160205_133 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_16a_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160206_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002526_1 Sex:1 | Treatment:1 SubjectID=50734; RAW_FILE_NAME=VT_160206_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002522_1 Sex:1 | Treatment:- SubjectID=50699; RAW_FILE_NAME=VT_160206_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002554_1 Sex:1 | Treatment:- SubjectID=51208; RAW_FILE_NAME=VT_160206_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002550_1 Sex:1 | Treatment:1 SubjectID=51173; RAW_FILE_NAME=VT_160206_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006202_1 Sex:1 | Treatment:- SubjectID=50835; RAW_FILE_NAME=VT_160206_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006142_1 Sex:1 | Treatment:2 SubjectID=51219; RAW_FILE_NAME=VT_160206_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000705_1 Sex:1 | Treatment:1 SubjectID=50734; RAW_FILE_NAME=VT_160206_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002546_1 Sex:1 | Treatment:2 SubjectID=51130; RAW_FILE_NAME=VT_160206_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002547_1 Sex:2 | Treatment:- SubjectID=51151; RAW_FILE_NAME=VT_160206_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002556_1 Sex:1 | Treatment:2 SubjectID=51219; RAW_FILE_NAME=VT_160206_061 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_16b_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160206_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002513_1 Sex:1 | Treatment:2 SubjectID=50622; RAW_FILE_NAME=VT_160206_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002542_1 Sex:1 | Treatment:- SubjectID=50835; RAW_FILE_NAME=VT_160206_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006237_1 Sex:1 | Treatment:1 SubjectID=51173; RAW_FILE_NAME=VT_160206_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105827_1 Sex:1 | Treatment:- SubjectID=51208; RAW_FILE_NAME=VT_160206_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106633_1 Sex:1 | Treatment:1 SubjectID=51162; RAW_FILE_NAME=VT_160206_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006051_1 Sex:1 | Treatment:2 SubjectID=50622; RAW_FILE_NAME=VT_160206_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000698_1 Sex:1 | Treatment:- SubjectID=50699; RAW_FILE_NAME=VT_160206_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105819_1 Sex:1 | Treatment:2 SubjectID=51130; RAW_FILE_NAME=VT_160206_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002549_1 Sex:1 | Treatment:1 SubjectID=51162; RAW_FILE_NAME=VT_160206_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006236_1 Sex:2 | Treatment:- SubjectID=51151; RAW_FILE_NAME=VT_160206_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_16c_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160206_133 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_17a_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160208_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001659_1 Sex:2 | Treatment:1 SubjectID=60050; RAW_FILE_NAME=VT_160208_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002575_1 Sex:1 | Treatment:2 SubjectID=51342; RAW_FILE_NAME=VT_160208_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001006_1 Sex:2 | Treatment:- SubjectID=30014; RAW_FILE_NAME=VT_160208_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002631_1 Sex:1 | Treatment:1 SubjectID=60689; RAW_FILE_NAME=VT_160208_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001653_1 Sex:1 | Treatment:1 SubjectID=60028; RAW_FILE_NAME=VT_160208_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002591_1 Sex:2 | Treatment:1 SubjectID=60050; RAW_FILE_NAME=VT_160208_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006369_1 Sex:1 | Treatment:2 SubjectID=51400; RAW_FILE_NAME=VT_160208_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002581_1 Sex:1 | Treatment:2 SubjectID=51400; RAW_FILE_NAME=VT_160208_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001651_1 Sex:1 | Treatment:2 SubjectID=51342; RAW_FILE_NAME=VT_160208_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002567_1 Sex:1 | Treatment:1 SubjectID=51285; RAW_FILE_NAME=VT_160208_061 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_17b_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160208_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002588_1 Sex:1 | Treatment:2 SubjectID=60039; RAW_FILE_NAME=VT_160208_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105842_1 Sex:1 | Treatment:1 SubjectID=51285; RAW_FILE_NAME=VT_160208_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002560_1 Sex:2 | Treatment:- SubjectID=51241; RAW_FILE_NAME=VT_160208_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002585_1 Sex:1 | Treatment:1 SubjectID=60028; RAW_FILE_NAME=VT_160208_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003059_1 Sex:2 | Treatment:- SubjectID=30014; RAW_FILE_NAME=VT_160208_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001655_1 Sex:1 | Treatment:2 SubjectID=60039; RAW_FILE_NAME=VT_160208_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006432_1 Sex:2 | Treatment:1 SubjectID=51310; RAW_FILE_NAME=VT_160208_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002751_1 Sex:2 | Treatment:1 SubjectID=51310; RAW_FILE_NAME=VT_160208_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40021552_1 Sex:2 | Treatment:- SubjectID=51241; RAW_FILE_NAME=VT_160208_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105656_1 Sex:1 | Treatment:1 SubjectID=60689; RAW_FILE_NAME=VT_160208_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_17c_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160208_133 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_18a_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160210_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000277_1 Sex:1 | Treatment:1 SubjectID=20731; RAW_FILE_NAME=VT_160210_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003367_1 Sex:1 | Treatment:1 SubjectID=20731; RAW_FILE_NAME=VT_160210_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005529_1 Sex:2 | Treatment:1 SubjectID=20584; RAW_FILE_NAME=VT_160210_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003345_1 Sex:1 | Treatment:1 SubjectID=20551; RAW_FILE_NAME=VT_160210_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003437_1 Sex:1 | Treatment:- SubjectID=20035; RAW_FILE_NAME=VT_160210_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005456_1 Sex:1 | Treatment:1 SubjectID=20417; RAW_FILE_NAME=VT_160210_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000274_1 Sex:1 | Treatment:- SubjectID=20709; RAW_FILE_NAME=VT_160210_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000466_1 Sex:1 | Treatment:2 SubjectID=20494; RAW_FILE_NAME=VT_160210_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003331_1 Sex:1 | Treatment:1 SubjectID=20417; RAW_FILE_NAME=VT_160210_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003362_1 Sex:1 | Treatment:- SubjectID=20709; RAW_FILE_NAME=VT_160210_061 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_18b_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160210_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003339_1 Sex:1 | Treatment:2 SubjectID=20494; RAW_FILE_NAME=VT_160210_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003359_1 Sex:2 | Treatment:1 SubjectID=20630; RAW_FILE_NAME=VT_160210_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000473_1 Sex:1 | Treatment:1 SubjectID=20551; RAW_FILE_NAME=VT_160210_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000490_1 Sex:2 | Treatment:1 SubjectID=20630; RAW_FILE_NAME=VT_160210_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000285_1 Sex:2 | Treatment:2 SubjectID=20797; RAW_FILE_NAME=VT_160210_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003374_1 Sex:2 | Treatment:2 SubjectID=20797; RAW_FILE_NAME=VT_160210_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003336_1 Sex:2 | Treatment:2 SubjectID=20483; RAW_FILE_NAME=VT_160210_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106617_1 Sex:2 | Treatment:2 SubjectID=20483; RAW_FILE_NAME=VT_160210_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000870_1 Sex:1 | Treatment:- SubjectID=20035; RAW_FILE_NAME=VT_160210_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003350_1 Sex:2 | Treatment:1 SubjectID=20584; RAW_FILE_NAME=VT_160210_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_18c_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160210_133 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_19a_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160213_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003483_1 Sex:2 | Treatment:2 SubjectID=11483; RAW_FILE_NAME=VT_160213_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106064_1 Sex:1 | Treatment:1 SubjectID=10370; RAW_FILE_NAME=VT_160213_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000739_1 Sex:1 | Treatment:2 SubjectID=10023; RAW_FILE_NAME=VT_160213_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003452_1 Sex:2 | Treatment:2 SubjectID=20147; RAW_FILE_NAME=VT_160213_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005486_1 Sex:2 | Treatment:2 SubjectID=20147; RAW_FILE_NAME=VT_160213_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003513_1 Sex:1 | Treatment:- SubjectID=10078; RAW_FILE_NAME=VT_160213_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003462_1 Sex:1 | Treatment:1 SubjectID=20316; RAW_FILE_NAME=VT_160213_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000741_1 Sex:1 | Treatment:1 SubjectID=10034; RAW_FILE_NAME=VT_160213_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003505_1 Sex:1 | Treatment:2 SubjectID=10023; RAW_FILE_NAME=VT_160213_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005564_1 Sex:1 | Treatment:1 SubjectID=20316; RAW_FILE_NAME=VT_160213_061 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_19b_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160213_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003538_1 Sex:1 | Treatment:1 SubjectID=10370; RAW_FILE_NAME=VT_160213_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106701_1 Sex:1 | Treatment:1 SubjectID=10517; RAW_FILE_NAME=VT_160213_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003521_1 Sex:1 | Treatment:2 SubjectID=10157; RAW_FILE_NAME=VT_160213_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015178_1 Sex:2 | Treatment:2 SubjectID=11483; RAW_FILE_NAME=VT_160213_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000749_1 Sex:1 | Treatment:- SubjectID=10078; RAW_FILE_NAME=VT_160213_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106299_1 Sex:1 | Treatment:2 SubjectID=11507; RAW_FILE_NAME=VT_160213_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003487_1 Sex:1 | Treatment:2 SubjectID=11507; RAW_FILE_NAME=VT_160213_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000759_1 Sex:1 | Treatment:2 SubjectID=10157; RAW_FILE_NAME=VT_160213_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003506_1 Sex:1 | Treatment:1 SubjectID=10034; RAW_FILE_NAME=VT_160213_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003555_1 Sex:1 | Treatment:1 SubjectID=10517; RAW_FILE_NAME=VT_160213_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_19c_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160213_133 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_20a_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160214_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106729_1 Sex:2 | Treatment:- SubjectID=10730; RAW_FILE_NAME=VT_160214_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003635_1 Sex:2 | Treatment:2 SubjectID=21047; RAW_FILE_NAME=VT_160214_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000945_1 Sex:1 | Treatment:2 SubjectID=21192; RAW_FILE_NAME=VT_160214_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003608_1 Sex:1 | Treatment:2 SubjectID=10695; RAW_FILE_NAME=VT_160214_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005601_1 Sex:2 | Treatment:2 SubjectID=21047; RAW_FILE_NAME=VT_160214_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005380_1 Sex:2 | Treatment:- SubjectID=10673; RAW_FILE_NAME=VT_160214_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005413_1 Sex:1 | Treatment:2 SubjectID=10695; RAW_FILE_NAME=VT_160214_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106711_1 Sex:1 | Treatment:1 SubjectID=10630; RAW_FILE_NAME=VT_160214_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106276_1 Sex:1 | Treatment:- SubjectID=11327; RAW_FILE_NAME=VT_160214_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005639_1 Sex:2 | Treatment:2 SubjectID=20988; RAW_FILE_NAME=VT_160214_061 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_20b_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160214_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003565_1 Sex:1 | Treatment:1 SubjectID=10630; RAW_FILE_NAME=VT_160214_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106762_1 Sex:2 | Treatment:2 SubjectID=10998; RAW_FILE_NAME=VT_160214_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003597_1 Sex:1 | Treatment:- SubjectID=11327; RAW_FILE_NAME=VT_160214_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003603_1 Sex:2 | Treatment:- SubjectID=10673; RAW_FILE_NAME=VT_160214_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003558_1 Sex:1 | Treatment:2 SubjectID=10583; RAW_FILE_NAME=VT_160214_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003627_1 Sex:2 | Treatment:2 SubjectID=20988; RAW_FILE_NAME=VT_160214_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106707_1 Sex:1 | Treatment:2 SubjectID=10583; RAW_FILE_NAME=VT_160214_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003649_1 Sex:1 | Treatment:2 SubjectID=21192; RAW_FILE_NAME=VT_160214_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003566_1 Sex:2 | Treatment:2 SubjectID=10998; RAW_FILE_NAME=VT_160214_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003611_1 Sex:2 | Treatment:- SubjectID=10730; RAW_FILE_NAME=VT_160214_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_20c_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160214_133 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_21a_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160215_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105868_1 Sex:2 | Treatment:1 SubjectID=21282; RAW_FILE_NAME=VT_160215_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005696_1 Sex:1 | Treatment:- SubjectID=21473; RAW_FILE_NAME=VT_160215_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003662_1 Sex:2 | Treatment:- SubjectID=21271; RAW_FILE_NAME=VT_160215_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003685_1 Sex:1 | Treatment:- SubjectID=21430; RAW_FILE_NAME=VT_160215_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40007282_1 Sex:2 | Treatment:1 SubjectID=21429; RAW_FILE_NAME=VT_160215_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003683_1 Sex:2 | Treatment:1 SubjectID=21429; RAW_FILE_NAME=VT_160215_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005697_1 Sex:2 | Treatment:- SubjectID=21451; RAW_FILE_NAME=VT_160215_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003670_1 Sex:1 | Treatment:1 SubjectID=21340; RAW_FILE_NAME=VT_160215_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005628_1 Sex:2 | Treatment:- SubjectID=21271; RAW_FILE_NAME=VT_160215_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003689_1 Sex:2 | Treatment:- SubjectID=21451; RAW_FILE_NAME=VT_160215_061 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_21b_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160215_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005631_1 Sex:1 | Treatment:1 SubjectID=21340; RAW_FILE_NAME=VT_160215_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003653_1 Sex:1 | Treatment:- SubjectID=21216; RAW_FILE_NAME=VT_160215_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105873_1 Sex:1 | Treatment:1 SubjectID=21317; RAW_FILE_NAME=VT_160215_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000339_1 Sex:1 | Treatment:- SubjectID=21216; RAW_FILE_NAME=VT_160215_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003665_1 Sex:2 | Treatment:1 SubjectID=21282; RAW_FILE_NAME=VT_160215_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003668_1 Sex:1 | Treatment:1 SubjectID=21317; RAW_FILE_NAME=VT_160215_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003691_1 Sex:1 | Treatment:- SubjectID=21473; RAW_FILE_NAME=VT_160215_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003654_1 Sex:1 | Treatment:- SubjectID=21227; RAW_FILE_NAME=VT_160215_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005593_1 Sex:1 | Treatment:- SubjectID=21430; RAW_FILE_NAME=VT_160215_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015101_1 Sex:1 | Treatment:- SubjectID=21227; RAW_FILE_NAME=VT_160215_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_21c_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160215_133 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_22a_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160216_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003733_1 Sex:1 | Treatment:2 SubjectID=21888; RAW_FILE_NAME=VT_160216_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001011_1 Sex:2 | Treatment:2 SubjectID=30047; RAW_FILE_NAME=VT_160216_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005762_1 Sex:2 | Treatment:2 SubjectID=30508; RAW_FILE_NAME=VT_160216_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005970_1 Sex:2 | Treatment:1 SubjectID=30710; RAW_FILE_NAME=VT_160216_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003774_1 Sex:2 | Treatment:- SubjectID=30238; RAW_FILE_NAME=VT_160216_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003803_1 Sex:2 | Treatment:1 SubjectID=30710; RAW_FILE_NAME=VT_160216_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105607_1 Sex:1 | Treatment:2 SubjectID=30574; RAW_FILE_NAME=VT_160216_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003779_1 Sex:1 | Treatment:- SubjectID=30340; RAW_FILE_NAME=VT_160216_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001025_1 Sex:2 | Treatment:- SubjectID=30238; RAW_FILE_NAME=VT_160216_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005726_1 Sex:1 | Treatment:- SubjectID=30340; RAW_FILE_NAME=VT_160216_061 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_22b_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160216_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003791_1 Sex:1 | Treatment:2 SubjectID=30574; RAW_FILE_NAME=VT_160216_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105906_1 Sex:2 | Treatment:2 SubjectID=21541; RAW_FILE_NAME=VT_160216_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005821_1 Sex:1 | Treatment:- SubjectID=30732; RAW_FILE_NAME=VT_160216_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003700_1 Sex:2 | Treatment:2 SubjectID=21541; RAW_FILE_NAME=VT_160216_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000991_1 Sex:1 | Treatment:1 SubjectID=21844; RAW_FILE_NAME=VT_160216_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003729_1 Sex:1 | Treatment:1 SubjectID=21844; RAW_FILE_NAME=VT_160216_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003806_1 Sex:2 | Treatment:2 SubjectID=30508; RAW_FILE_NAME=VT_160216_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105513_1 Sex:1 | Treatment:2 SubjectID=21888; RAW_FILE_NAME=VT_160216_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003805_1 Sex:1 | Treatment:- SubjectID=30732; RAW_FILE_NAME=VT_160216_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003761_1 Sex:2 | Treatment:2 SubjectID=30047; RAW_FILE_NAME=VT_160216_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_22c_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160216_133 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_23a_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160217_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015624_1 Sex:1 | Treatment:1 SubjectID=30989; RAW_FILE_NAME=VT_160217_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005426_1 Sex:1 | Treatment:- SubjectID=11191; RAW_FILE_NAME=VT_160217_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003824_1 Sex:1 | Treatment:1 SubjectID=30989; RAW_FILE_NAME=VT_160217_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005402_1 Sex:1 | Treatment:1 SubjectID=11281; RAW_FILE_NAME=VT_160217_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005399_1 Sex:2 | Treatment:2 SubjectID=10629; RAW_FILE_NAME=VT_160217_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000750_1 Sex:1 | Treatment:- SubjectID=10089; RAW_FILE_NAME=VT_160217_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005331_1 Sex:1 | Treatment:- SubjectID=10607; RAW_FILE_NAME=VT_160217_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005504_1 Sex:2 | Treatment:2 SubjectID=20204; RAW_FILE_NAME=VT_160217_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003807_1 Sex:2 | Treatment:1 SubjectID=30776; RAW_FILE_NAME=VT_160217_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000799_1 Sex:1 | Treatment:- SubjectID=10607; RAW_FILE_NAME=VT_160217_061 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_23b_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160217_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000838_1 Sex:1 | Treatment:- SubjectID=11191; RAW_FILE_NAME=VT_160217_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005822_1 Sex:2 | Treatment:1 SubjectID=30776; RAW_FILE_NAME=VT_160217_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106758_1 Sex:1 | Treatment:1 SubjectID=10965; RAW_FILE_NAME=VT_160217_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005296_1 Sex:1 | Treatment:1 SubjectID=10405; RAW_FILE_NAME=VT_160217_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005376_1 Sex:1 | Treatment:1 SubjectID=10965; RAW_FILE_NAME=VT_160217_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106068_1 Sex:1 | Treatment:1 SubjectID=10405; RAW_FILE_NAME=VT_160217_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000801_1 Sex:2 | Treatment:2 SubjectID=10629; RAW_FILE_NAME=VT_160217_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015065_1 Sex:1 | Treatment:1 SubjectID=11281; RAW_FILE_NAME=VT_160217_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005328_1 Sex:1 | Treatment:- SubjectID=10089; RAW_FILE_NAME=VT_160217_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000431_1 Sex:2 | Treatment:2 SubjectID=20204; RAW_FILE_NAME=VT_160217_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_23c_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160217_133 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_24a_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160218_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000475_1 Sex:1 | Treatment:2 SubjectID=20562; RAW_FILE_NAME=VT_160218_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005621_1 Sex:1 | Treatment:2 SubjectID=21238; RAW_FILE_NAME=VT_160218_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106611_1 Sex:2 | Treatment:2 SubjectID=21025; RAW_FILE_NAME=VT_160218_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105567_1 Sex:1 | Treatment:1 SubjectID=30271; RAW_FILE_NAME=VT_160218_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005573_1 Sex:1 | Treatment:2 SubjectID=20562; RAW_FILE_NAME=VT_160218_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000276_1 Sex:1 | Treatment:2 SubjectID=20710; RAW_FILE_NAME=VT_160218_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005642_1 Sex:1 | Treatment:1 SubjectID=21104; RAW_FILE_NAME=VT_160218_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005549_1 Sex:1 | Treatment:2 SubjectID=20710; RAW_FILE_NAME=VT_160218_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005574_1 Sex:1 | Treatment:- SubjectID=20608; RAW_FILE_NAME=VT_160218_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005605_1 Sex:1 | Treatment:2 SubjectID=21238; RAW_FILE_NAME=VT_160218_061 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_24b_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160218_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000330_1 Sex:1 | Treatment:1 SubjectID=21104; RAW_FILE_NAME=VT_160218_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000299_1 Sex:2 | Treatment:1 SubjectID=20900; RAW_FILE_NAME=VT_160218_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005741_1 Sex:1 | Treatment:1 SubjectID=30271; RAW_FILE_NAME=VT_160218_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005777_1 Sex:1 | Treatment:2 SubjectID=30070; RAW_FILE_NAME=VT_160218_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106284_1 Sex:1 | Treatment:- SubjectID=11360; RAW_FILE_NAME=VT_160218_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001013_1 Sex:1 | Treatment:2 SubjectID=30070; RAW_FILE_NAME=VT_160218_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005615_1 Sex:2 | Treatment:1 SubjectID=20900; RAW_FILE_NAME=VT_160218_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000483_1 Sex:1 | Treatment:- SubjectID=20608; RAW_FILE_NAME=VT_160218_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005513_1 Sex:1 | Treatment:- SubjectID=11360; RAW_FILE_NAME=VT_160218_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005617_1 Sex:2 | Treatment:2 SubjectID=21025; RAW_FILE_NAME=VT_160218_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_24c_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160218_133 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_25a_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160220_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005902_1 Sex:2 | Treatment:2 SubjectID=40048; RAW_FILE_NAME=VT_160220_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005871_1 Sex:1 | Treatment:1 SubjectID=40362; RAW_FILE_NAME=VT_160220_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005781_1 Sex:1 | Treatment:2 SubjectID=21675; RAW_FILE_NAME=VT_160220_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005785_1 Sex:1 | Treatment:1 SubjectID=21956; RAW_FILE_NAME=VT_160220_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005779_1 Sex:2 | Treatment:2 SubjectID=30383; RAW_FILE_NAME=VT_160220_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005818_1 Sex:1 | Treatment:- SubjectID=30754; RAW_FILE_NAME=VT_160220_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005768_1 Sex:1 | Treatment:1 SubjectID=21956; RAW_FILE_NAME=VT_160220_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005783_1 Sex:1 | Treatment:1 SubjectID=21811; RAW_FILE_NAME=VT_160220_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005763_1 Sex:1 | Treatment:2 SubjectID=21675; RAW_FILE_NAME=VT_160220_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005854_1 Sex:1 | Treatment:1 SubjectID=40362; RAW_FILE_NAME=VT_160220_061 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_25b_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160220_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105626_1 Sex:2 | Treatment:2 SubjectID=30721; RAW_FILE_NAME=VT_160220_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105503_1 Sex:1 | Treatment:1 SubjectID=21811; RAW_FILE_NAME=VT_160220_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015684_1 Sex:1 | Treatment:- SubjectID=30754; RAW_FILE_NAME=VT_160220_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005855_1 Sex:1 | Treatment:1 SubjectID=40408; RAW_FILE_NAME=VT_160220_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005846_1 Sex:1 | Treatment:1 SubjectID=30260; RAW_FILE_NAME=VT_160220_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005872_1 Sex:1 | Treatment:1 SubjectID=40408; RAW_FILE_NAME=VT_160220_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005761_1 Sex:2 | Treatment:2 SubjectID=30383; RAW_FILE_NAME=VT_160220_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005832_1 Sex:1 | Treatment:1 SubjectID=30260; RAW_FILE_NAME=VT_160220_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001410_1 Sex:2 | Treatment:2 SubjectID=40048; RAW_FILE_NAME=VT_160220_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005878_1 Sex:2 | Treatment:2 SubjectID=30721; RAW_FILE_NAME=VT_160220_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_25c_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160220_133 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_26a_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160222_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40016058_1 Sex:1 | Treatment:2 SubjectID=41486; RAW_FILE_NAME=VT_160222_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001498_1 Sex:1 | Treatment:2 SubjectID=41106; RAW_FILE_NAME=VT_160222_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006107_1 Sex:1 | Treatment:2 SubjectID=40520; RAW_FILE_NAME=VT_160222_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005923_1 Sex:1 | Treatment:2 SubjectID=41486; RAW_FILE_NAME=VT_160222_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000397_1 Sex:1 | Treatment:1 SubjectID=40990; RAW_FILE_NAME=VT_160222_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006008_1 Sex:1 | Treatment:1 SubjectID=31026; RAW_FILE_NAME=VT_160222_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001408_1 Sex:1 | Treatment:1 SubjectID=40037; RAW_FILE_NAME=VT_160222_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000658_1 Sex:1 | Treatment:2 SubjectID=40520; RAW_FILE_NAME=VT_160222_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006045_1 Sex:1 | Treatment:- SubjectID=41218; RAW_FILE_NAME=VT_160222_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000374_1 Sex:1 | Treatment:1 SubjectID=40812; RAW_FILE_NAME=VT_160222_061 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_26b_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160222_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006015_1 Sex:1 | Treatment:1 SubjectID=40812; RAW_FILE_NAME=VT_160222_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006080_1 Sex:2 | Treatment:- SubjectID=41284; RAW_FILE_NAME=VT_160222_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006043_1 Sex:1 | Treatment:1 SubjectID=40037; RAW_FILE_NAME=VT_160222_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015702_1 Sex:1 | Treatment:1 SubjectID=31026; RAW_FILE_NAME=VT_160222_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006112_1 Sex:1 | Treatment:2 SubjectID=41106; RAW_FILE_NAME=VT_160222_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005985_1 Sex:1 | Treatment:- SubjectID=41218; RAW_FILE_NAME=VT_160222_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000617_1 Sex:2 | Treatment:- SubjectID=40240; RAW_FILE_NAME=VT_160222_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005997_1 Sex:1 | Treatment:1 SubjectID=40990; RAW_FILE_NAME=VT_160222_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006102_1 Sex:2 | Treatment:- SubjectID=41284; RAW_FILE_NAME=VT_160222_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005930_1 Sex:2 | Treatment:- SubjectID=40240; RAW_FILE_NAME=VT_160222_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_26c_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160222_133 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_27a_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160223_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006161_1 Sex:1 | Treatment:- SubjectID=50284; RAW_FILE_NAME=VT_160223_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40014530_1 Sex:1 | Treatment:- SubjectID=50251; RAW_FILE_NAME=VT_160223_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006272_1 Sex:2 | Treatment:1 SubjectID=50756; RAW_FILE_NAME=VT_160223_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105830_1 Sex:1 | Treatment:- SubjectID=51220; RAW_FILE_NAME=VT_160223_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006327_1 Sex:1 | Treatment:- SubjectID=60375; RAW_FILE_NAME=VT_160223_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006438_1 Sex:1 | Treatment:- SubjectID=60645; RAW_FILE_NAME=VT_160223_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006245_1 Sex:1 | Treatment:- SubjectID=51220; RAW_FILE_NAME=VT_160223_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105774_1 Sex:1 | Treatment:1 SubjectID=60454; RAW_FILE_NAME=VT_160223_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006147_1 Sex:1 | Treatment:- SubjectID=50284; RAW_FILE_NAME=VT_160223_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006540_1 Sex:2 | Treatment:2 SubjectID=60904; RAW_FILE_NAME=VT_160223_061 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_27b_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160223_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006233_1 Sex:2 | Treatment:- SubjectID=50969; RAW_FILE_NAME=VT_160223_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006216_1 Sex:2 | Treatment:- SubjectID=50969; RAW_FILE_NAME=VT_160223_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006211_1 Sex:2 | Treatment:2 SubjectID=41790; RAW_FILE_NAME=VT_160223_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006519_1 Sex:1 | Treatment:1 SubjectID=60454; RAW_FILE_NAME=VT_160223_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106472_1 Sex:2 | Treatment:2 SubjectID=41790; RAW_FILE_NAME=VT_160223_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006422_1 Sex:1 | Treatment:- SubjectID=60645; RAW_FILE_NAME=VT_160223_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001696_1 Sex:1 | Treatment:- SubjectID=60375; RAW_FILE_NAME=VT_160223_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006523_1 Sex:2 | Treatment:2 SubjectID=60904; RAW_FILE_NAME=VT_160223_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006286_1 Sex:2 | Treatment:1 SubjectID=50756; RAW_FILE_NAME=VT_160223_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006120_1 Sex:1 | Treatment:- SubjectID=50251; RAW_FILE_NAME=VT_160223_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_27c_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160223_133 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_28a_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160224_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000218_1 Sex:1 | Treatment:- SubjectID=71085; RAW_FILE_NAME=VT_160224_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106515_1 Sex:1 | Treatment:- SubjectID=50295; RAW_FILE_NAME=VT_160224_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015871_1 Sex:1 | Treatment:2 SubjectID=90514; RAW_FILE_NAME=VT_160224_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006854_1 Sex:1 | Treatment:- SubjectID=90277; RAW_FILE_NAME=VT_160224_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000565_1 Sex:1 | Treatment:- SubjectID=90200; RAW_FILE_NAME=VT_160224_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006786_1 Sex:2 | Treatment:- SubjectID=41734; RAW_FILE_NAME=VT_160224_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006773_1 Sex:1 | Treatment:- SubjectID=50295; RAW_FILE_NAME=VT_160224_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006802_1 Sex:2 | Treatment:2 SubjectID=50778; RAW_FILE_NAME=VT_160224_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006818_1 Sex:1 | Treatment:1 SubjectID=41756; RAW_FILE_NAME=VT_160224_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006624_1 Sex:1 | Treatment:- SubjectID=70590; RAW_FILE_NAME=VT_160224_061 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_28b_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160224_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006873_1 Sex:1 | Treatment:- SubjectID=90277; RAW_FILE_NAME=VT_160224_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006820_1 Sex:2 | Treatment:1 SubjectID=41633; RAW_FILE_NAME=VT_160224_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006768_1 Sex:2 | Treatment:- SubjectID=41734; RAW_FILE_NAME=VT_160224_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106248_1 Sex:2 | Treatment:1 SubjectID=41633; RAW_FILE_NAME=VT_160224_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006905_1 Sex:1 | Treatment:2 SubjectID=90514; RAW_FILE_NAME=VT_160224_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006650_1 Sex:1 | Treatment:- SubjectID=70590; RAW_FILE_NAME=VT_160224_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006649_1 Sex:1 | Treatment:- SubjectID=71085; RAW_FILE_NAME=VT_160224_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015457_1 Sex:1 | Treatment:1 SubjectID=41756; RAW_FILE_NAME=VT_160224_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006814_1 Sex:2 | Treatment:2 SubjectID=50778; RAW_FILE_NAME=VT_160224_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006736_1 Sex:1 | Treatment:- SubjectID=90200; RAW_FILE_NAME=VT_160224_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_28c_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160224_133 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_29a_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160225_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40007173_1 Sex:1 | Treatment:1 SubjectID=21912; RAW_FILE_NAME=VT_160225_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015231_1 Sex:1 | Treatment:2 SubjectID=91098; RAW_FILE_NAME=VT_160225_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40007009_1 Sex:1 | Treatment:- SubjectID=91111; RAW_FILE_NAME=VT_160225_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106158_1 Sex:1 | Treatment:1 SubjectID=90806; RAW_FILE_NAME=VT_160225_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40007065_1 Sex:1 | Treatment:- SubjectID=91256; RAW_FILE_NAME=VT_160225_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005355_1 Sex:1 | Treatment:2 SubjectID=11024; RAW_FILE_NAME=VT_160225_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40007164_1 Sex:1 | Treatment:1 SubjectID=90806; RAW_FILE_NAME=VT_160225_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40007033_1 Sex:1 | Treatment:2 SubjectID=91098; RAW_FILE_NAME=VT_160225_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40007078_1 Sex:1 | Treatment:- SubjectID=91256; RAW_FILE_NAME=VT_160225_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40007132_1 Sex:1 | Treatment:1 SubjectID=21912; RAW_FILE_NAME=VT_160225_061 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_29b_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160225_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006983_1 Sex:1 | Treatment:- SubjectID=91111; RAW_FILE_NAME=VT_160225_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40007098_1 Sex:1 | Treatment:1 SubjectID=91537; RAW_FILE_NAME=VT_160225_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40007138_1 Sex:1 | Treatment:- SubjectID=10720; RAW_FILE_NAME=VT_160225_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40007113_1 Sex:1 | Treatment:2 SubjectID=91480; RAW_FILE_NAME=VT_160225_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106576_1 Sex:1 | Treatment:1 SubjectID=91537; RAW_FILE_NAME=VT_160225_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40007021_1 Sex:1 | Treatment:2 SubjectID=91087; RAW_FILE_NAME=VT_160225_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40007041_1 Sex:1 | Treatment:2 SubjectID=91087; RAW_FILE_NAME=VT_160225_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015434_1 Sex:1 | Treatment:- SubjectID=10720; RAW_FILE_NAME=VT_160225_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40007140_1 Sex:1 | Treatment:2 SubjectID=11024; RAW_FILE_NAME=VT_160225_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40007101_1 Sex:1 | Treatment:2 SubjectID=91480; RAW_FILE_NAME=VT_160225_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_29c_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160225_133 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_30a_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160226_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40022359_1 Sex:1 | Treatment:- SubjectID=50172; RAW_FILE_NAME=VT_160226_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40014517_1 Sex:1 | Treatment:- SubjectID=10090; RAW_FILE_NAME=VT_160226_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105900_1 Sex:1 | Treatment:1 SubjectID=21519; RAW_FILE_NAME=VT_160226_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40022876_1 Sex:1 | Treatment:1 SubjectID=21519; RAW_FILE_NAME=VT_160226_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105724_1 Sex:1 | Treatment:- SubjectID=60118; RAW_FILE_NAME=VT_160226_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001569_1 Sex:1 | Treatment:1 SubjectID=50117; RAW_FILE_NAME=VT_160226_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40022468_1 Sex:1 | Treatment:1 SubjectID=50117; RAW_FILE_NAME=VT_160226_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015971_1 Sex:1 | Treatment:2 SubjectID=70321; RAW_FILE_NAME=VT_160226_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40022495_1 Sex:1 | Treatment:2 SubjectID=40250; RAW_FILE_NAME=VT_160226_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40022374_1 Sex:1 | Treatment:2 SubjectID=60432; RAW_FILE_NAME=VT_160226_061 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_30b_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160226_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006789_1 Sex:1 | Treatment:- SubjectID=50172; RAW_FILE_NAME=VT_160226_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001440_1 Sex:1 | Treatment:2 SubjectID=40250; RAW_FILE_NAME=VT_160226_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40022363_1 Sex:2 | Treatment:- SubjectID=20270; RAW_FILE_NAME=VT_160226_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40022384_1 Sex:2 | Treatment:1 SubjectID=30350; RAW_FILE_NAME=VT_160226_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106024_1 Sex:1 | Treatment:- SubjectID=10090; RAW_FILE_NAME=VT_160226_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40022734_1 Sex:1 | Treatment:2 SubjectID=70321; RAW_FILE_NAME=VT_160226_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40022462_1 Sex:1 | Treatment:- SubjectID=60118; RAW_FILE_NAME=VT_160226_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005890_1 Sex:2 | Treatment:1 SubjectID=30350; RAW_FILE_NAME=VT_160226_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105771_1 Sex:1 | Treatment:2 SubjectID=60432; RAW_FILE_NAME=VT_160226_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000892_1 Sex:2 | Treatment:- SubjectID=20270; RAW_FILE_NAME=VT_160226_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_30c_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160226_133 SUBJECT_SAMPLE_FACTORS Quality Control nist2_1 Sex:NA | Treatment:NA SubjectID=NA; RAW_FILE_NAME=VT_160226_139 #COLLECTION CO:COLLECTION_SUMMARY Blood plasma samples were collected from non-fasting participants in the CO:COLLECTION_SUMMARY Aspirin/Folate Polyp Prevention Study at enrollment (baseline) and after three CO:COLLECTION_SUMMARY years of study treatment. Blood samples were collected in tubes containing EDTA CO:COLLECTION_SUMMARY and after centrifugation aliquots of plasma were transferred to 1.8ml freezer CO:COLLECTION_SUMMARY tubes and stored frozen at -20C or lower. The samples were shipped on dry ice CO:COLLECTION_SUMMARY from the clinical centers to the Dartmouth biorepository storage facility (for CO:COLLECTION_SUMMARY storage at -70C) and subsequently to the metabolimics analysis lab at Emory CO:COLLECTION_SUMMARY University. CO:SAMPLE_TYPE Blood (plasma) CO:STORAGE_CONDITIONS Described in summary #TREATMENT TR:TREATMENT_SUMMARY Samples were received frozen in aliquouts of <250uL. Prior to analysis, samples TR:TREATMENT_SUMMARY were thawed and prepared for HRM analysis using the standard protocols described TR:TREATMENT_SUMMARY in the Sample Preparation section. #SAMPLEPREP SP:SAMPLEPREP_SUMMARY Samples were prepared for metabolomics analysis using established SP:SAMPLEPREP_SUMMARY methods(Johnson et al. (2010). Analyst; Go et al. (2015). Tox Sci). Prior to SP:SAMPLEPREP_SUMMARY analysis, plasma aliquots were removed from storage at -80 degrees C and thawed SP:SAMPLEPREP_SUMMARY on ice. Each cryotube was then vortexed briefly to ensure homogeneity, and 50 SP:SAMPLEPREP_SUMMARY microliters was transferred to a clean microfuge tube. Immediately after, the SP:SAMPLEPREP_SUMMARY plasma was treated with 100 microliters of ice-cold LC-MS grade acetonitrile SP:SAMPLEPREP_SUMMARY (Sigma Aldrich) containing 2.5 microliters of internal standard solution with SP:SAMPLEPREP_SUMMARY eight stable isotopic chemicals selected to cover a range of chemical SP:SAMPLEPREP_SUMMARY properties. Following addition of acetonitrile, urine was equilibrated for 30min SP:SAMPLEPREP_SUMMARY on ice, upon which precipitated proteins were removed by centrifuge (14,000rpm SP:SAMPLEPREP_SUMMARY at 4 degrees C for 10 min). The resulting supernatant (100 microliters) was SP:SAMPLEPREP_SUMMARY removed, added to a low volume autosampler vial and maintained at 4 degrees C SP:SAMPLEPREP_SUMMARY until analysis (<22 h). SP:SAMPLEPREP_PROTOCOL_ID HRM_SP_082016_01 SP:SAMPLEPREP_PROTOCOL_FILENAME EmoryUniversity_HRM_SP_082016_01.pdf SP:SAMPLEPREP_PROTOCOL_COMMENTS Date effective: 30 July 2016 SP:EXTRACTION_METHOD 2:1 acetonitrile: sample followed by vortexing and centrifugation #CHROMATOGRAPHY CH:CHROMATOGRAPHY_SUMMARY The C18 column is operated parallel to the HILIC column for simultaneous CH:CHROMATOGRAPHY_SUMMARY analytical separation and column flushing through the use of a dual head HPLC CH:CHROMATOGRAPHY_SUMMARY pump equipped with 10-port and 6- port switching valves. During operation of the CH:CHROMATOGRAPHY_SUMMARY C18 method, the MS is operated in negative ion mode and 10 uL of sample is CH:CHROMATOGRAPHY_SUMMARY injected onto the C18 column while the HILIC column is flushing with wash CH:CHROMATOGRAPHY_SUMMARY solution. Flow rate is maintained at 0.35 mL/min until 2 min, increased to 0.4 CH:CHROMATOGRAPHY_SUMMARY mL/min at 6 min and held for 4 min. Solvent A is 100% LC-MS grade water, solvent CH:CHROMATOGRAPHY_SUMMARY B is 100% LC-MS grade acetonitrile and solvent C is 2% formic acid (v/v) in CH:CHROMATOGRAPHY_SUMMARY LC-MS grade water. Initial mobile phase conditions are 80% A, 15% B, 5% C hold CH:CHROMATOGRAPHY_SUMMARY for 0.5 min, with linear gradient to 0% A, 95% B, 5% C at 2 min, hold for 4min, CH:CHROMATOGRAPHY_SUMMARY resulting in a total analytical run time of 10 min. During the flushing phase CH:CHROMATOGRAPHY_SUMMARY (HILIC analytical separation), the C18 column is equilibrated with a wash CH:CHROMATOGRAPHY_SUMMARY solution of 0% A, 95% B, 5% C until 7.5 min, followed by an equilibration CH:CHROMATOGRAPHY_SUMMARY solution of 80% A, 15% B, 5% C for 2.5 min. CH:CHROMATOGRAPHY_TYPE Reversed phase CH:INSTRUMENT_NAME Dionex UltiMate 3000 CH:COLUMN_NAME Thermo Fisher Accucore C18 50x2.1mm 2.6u with Thermo accucore CH:FLOW_RATE 0.35 mL/min for 2 min; linear increase to 0.4 mL/min at 6 min held for 4 min CH:COLUMN_TEMPERATURE 60C CH:METHODS_FILENAME 20160120_posC18120kres10mim_ESI_hilicposwash_acore.meth CH:SOLVENT_A LC-MS grade water CH:SOLVENT_B LC-MS grade acetonitrile CH:SAMPLE_INJECTION 10 uL CH:ANALYTICAL_TIME 10 min CH:SAMPLE_LOOP_SIZE 15 uL CH:SAMPLE_SYRINGE_SIZE 100 uL #ANALYSIS AN:ANALYSIS_TYPE MS AN:LABORATORY_NAME Clinical Biomarkers Laboratory AN:OPERATOR_NAME Vilinh Tran AN:DETECTOR_TYPE Orbitrap AN:SOFTWARE_VERSION Xcalibur 3.0.63 AN:ACQUISITION_DATE 1/20/16-2/26/16 AN:ANALYSIS_PROTOCOL_FILE EmoryUniversity_HRM_QEHF-MS_092017_v1.pdf AN:DATA_FORMAT Profile #MS MS:INSTRUMENT_NAME Thermo Q Exactive HF hybrid Orbitrap MS:INSTRUMENT_TYPE Orbitrap MS:MS_TYPE ESI MS:ION_MODE POSITIVE MS:MS_COMMENTS None MS:CAPILLARY_TEMPERATURE 250C MS:COLLISION_GAS N2 MS:DRY_GAS_FLOW 45 MS:DRY_GAS_TEMP 150C MS:MASS_ACCURACY < 3ppm MS:SPRAY_VOLTAGE -4000 MS:ACTIVATION_PARAMETER 5.00E+05 MS:ACTIVATION_TIME 118ms MS:INTERFACE_VOLTAGE S-Lens RF level= 55 MS:MS_RESULTS_FILE ST001422_AN002379_Results.txt UNITS:peak area Has m/z:Yes Has RT:Yes RT units:Seconds #END